コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inal, catecholamine-secreting paraganglioma (pheochromocytoma).
2 umor), and hypertension (in the patient with pheochromocytoma).
3 ing tumor, testosterone-secreting tumor, and pheochromocytoma.
4 y (range, 25-68 y), with known or suspected pheochromocytoma.
5 riteria to distinguish benign from malignant pheochromocytoma.
6 o renal cell carcinoma, hemangioblastoma and pheochromocytoma.
7 ted tomography (CT) is useful for localizing pheochromocytoma.
8 ecially in neuroblastoma, paraganglioma, and pheochromocytoma.
9 o image adrenergic innervation and suspected pheochromocytoma.
10 approach for adrenalectomy in the setting of pheochromocytoma.
11 ns the treatment of choice for patients with pheochromocytoma.
12 mangioblastoma, renal cell carcinoma, and/or pheochromocytoma.
13 or formation in patients with MEN 2A-related pheochromocytoma.
14 an chromosome 1p that is implicated in human pheochromocytoma.
15 s an inherited cancer syndrome that includes pheochromocytoma.
16 h tumorigenesis in hereditary, MEN 2-related pheochromocytoma.
17 nderlying the pathogenesis of MEN 2A-related pheochromocytoma.
18 carcinoma, cyst adenomas of other organs and pheochromocytoma.
19 8X was found in a patient with extra-adrenal pheochromocytoma.
20 y analyses of human DCSV purified from human pheochromocytoma.
21 peutic target in the treatment of metastatic pheochromocytoma.
22 inhibitors for treatment of PTEN loss-driven pheochromocytoma.
23 sis and localization of benign and malignant pheochromocytomas.
24 r pathways that may be involved in malignant pheochromocytomas.
25 ith the clinical and pathologic groupings of pheochromocytomas.
26 marker for detection of benign and malignant pheochromocytomas.
27 ients underwent laparoscopic resection of 81 pheochromocytomas.
28 f a minimally invasive approach for sizeable pheochromocytomas.
29 VHL gene deletion in all four MEN 2A-related pheochromocytomas.
30 ous system, renal clear cell carcinomas, and pheochromocytomas.
31 in the tumorigenesis of some MEN 2A-related pheochromocytomas.
32 ioblastomas, clear cell renal carcinomas and pheochromocytomas.
33 (7-20% of families)] or absence (type 1) of pheochromocytomas.
34 nical Cushing syndrome and less likely to be pheochromocytomas.
35 1195 shows high and specific accumulation in pheochromocytomas.
36 articularly in patients with large tumors or pheochromocytomas.
39 ity of myocyte enhancer factor 2C (MEF2C) in pheochromocytoma 12 (PC12) cells and was required for ne
42 osphorylated after neurotrophin treatment of pheochromocytoma 12 cells and primary hippocampal neuron
45 p)) in which Lmx1b was only deleted in Pet1 (pheochromocytoma 12 ETS factor-1)-expressing 5-HT neuron
46 2 receptor in the survival of neurons: PC12 (pheochromocytoma 12) cells and dorsal root ganglion neur
47 my were functional tumors in 43 patients (20 pheochromocytomas, 13 Cushing disease or syndrome, and 1
49 5.1 vs 3.3 cm, respectively; P < .001), more pheochromocytomas (24 of 70 [35%] vs. 100 of 476 [21%],
50 ormed genome-wide expression profiling of 58 pheochromocytomas (29 benign and sporadic, 16 benign and
51 009) and a significantly lower prevalence of pheochromocytoma (4.3% [1 of 23] vs 19.6% [22 of 112]) (
52 following nerve growth factor stimulation of pheochromocytoma 6 (PC6) cells, Rit silencing selectivel
53 maging studies suggested that the mass was a pheochromocytoma, a cortical adrenal adenoma was histolo
54 previously identified in neuroblastomas and pheochromocytomas all fail to activate CN or stimulate D
56 idence for two novel susceptibility loci for pheochromocytoma and adds a recessive digenic trait to t
58 line mutations of these genes cause familial pheochromocytoma and other neural crest-derived tumors.
60 MDH2 has been recently identified as a novel pheochromocytoma and paraganglioma susceptibility gene.
64 eta missense mutations in neuroblastomas and pheochromocytomas and an acquired loss-of-function mutat
65 he sensitivity of (18)F-DOPA PET for adrenal pheochromocytomas and extraadrenal abdominal paraganglio
66 dopa also improves (18)F-DOPA PET of adrenal pheochromocytomas and extraadrenal paragangliomas is unk
69 comprehensive molecular characterization of pheochromocytomas and paragangliomas (PCCs/PGLs), a rare
75 ermore, we assessed whether the genotypes of pheochromocytomas and paragangliomas correlate with the
77 ng modality for the detection and staging of pheochromocytomas and paragangliomas in different genoty
78 Newly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127
80 plays a role in the development of sporadic pheochromocytomas and performed a mutation and deletion
81 between the microarray profiles of malignant pheochromocytomas and several known molecular pathways a
82 the FP/TMEM127 gene in 990 individuals with pheochromocytomas and/or paragangliomas, including 898 p
85 ed microarray expression analysis on benign (pheochromocytomas) and malignant (medullary thyroid carc
88 tumors, such as neuroblastoma, paraganglioma/pheochromocytoma, and carcinoids; and discuss approaches
89 d using three types of cells: neuroblastoma, pheochromocytoma, and Ewing's sarcoma family of tumors (
91 of neural progenitor cells of neuroblastoma, pheochromocytoma, and surrogate stem cell lineages from
92 patients with pancreatic NETs had associated pheochromocytomas, and 22 (88%) had no or mild pancreati
94 as of the retina and central nervous system, pheochromocytomas, and clear cell renal carcinoma, which
95 pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive
97 registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (63
103 s, loss of pVHL function may be causative in pheochromocytoma-associated hypercatecholaminemia and ar
105 mutations of FP/TMEM127 were associated with pheochromocytoma but not paraganglioma and occurred in a
106 ne potential (MMP) and ATP level in neuronal pheochromocytoma cell (PC12) models of oxidative and nit
110 e recombinant human alpha1 I domain, the rat pheochromocytoma cell line (PC12), and the rat glioma Ru
114 kin 5 promote neurite extension of the PC-12 pheochromocytoma cell line; this effect is abolished by
118 perform studies in a continuous chromaffin (pheochromocytoma) cell line, such as PC12, although such
119 ss of this transmitter-based prosthesis, rat pheochromocytoma cells (PC12 cell line) were grown on th
120 nstrated that nerve growth factor-primed rat pheochromocytoma cells (PC12) and explanted rat dorsal r
122 PAI-1 was prominently expressed in PC12 pheochromocytoma cells and bovine adrenomedullary chroma
123 that IGF-1 was able to induce HIF-1alpha in pheochromocytoma cells and cultured neurons as well as i
126 the identification of unique sections of rat pheochromocytoma cells exposed to the sample surface dur
127 th growth and differentiation of rat adrenal pheochromocytoma cells for sustained periods in culture.
128 nervous systems, and our previous data with pheochromocytoma cells implicate Rit signaling in NGF-in
129 easured this intermediate in clonal PC12 rat pheochromocytoma cells incubated with various concentrat
130 ce mediated knock-down of NPCD expression in pheochromocytoma cells inhibits NGF-induced neuronal pro
131 growth factor-NGF) signaling systems in PC12 pheochromocytoma cells that resulted in a translocation
132 ould coassemble with native P2X2 subunits in pheochromocytoma cells to form light-activated heteromer
133 of isofuranodiene towards rat neuronal PC-12 pheochromocytoma cells were determined by MTT assay, whi
139 hat promote neuronal differentiation of PC12 pheochromocytoma cells, we engineered a chimeric protein
140 e yeast model paralleled those from neuronal pheochromocytoma cells, where disruption of microtubules
151 ing gene FP/TMEM127 in familial and sporadic pheochromocytomas consistent with a tumor suppressor eff
157 mean follow-up of 57 months, a contralateral pheochromocytoma developed in four patients with MEN 2 (
159 expressed genes between benign and malignant pheochromocytomas distinguish between these tumors with
160 node metastases, an aortic dissection, and a pheochromocytoma; each of these findings was seen in one
163 rage (18)F-DOPA uptake by paragangliomas and pheochromocytomas, expressed as a tumor-to-liver ratio,
165 has been in clinical use for the imaging of pheochromocytoma for many years, a large multicenter eva
171 sis defect in the major hereditary groups of pheochromocytoma have provided a mechanistic basis for t
172 Importantly, insights into the biology of pheochromocytomas have provided clues on pathway interac
177 uanidine (MIBG) analog, for the detection of pheochromocytoma in a preclinical in vivo model of endog
178 an indication for thorough surveillance for pheochromocytoma in affected family members.The VHL gene
179 to deletions), therefore a family history of pheochromocytoma in association with VHL is an indicatio
180 to-oncogene cause familial predisposition to pheochromocytoma in multiple endocrine neoplasia type II
182 indicated the presence of paragangliomas and pheochromocytomas in 68 patients and the absence of a tu
184 e outcomes of laparoscopic adrenalectomy for pheochromocytomas in the largest study to date when perf
187 tion of a high rate of germline mutations in pheochromocytomas indicate that their genetic diversity
193 Although the etiology of most inherited pheochromocytoma is well known, little is known about th
196 4 neuroblastoma or metastatic paraganglioma/pheochromocytoma (MP) were treated using an institutiona
197 B or the synprint deletion mutant into mouse pheochromocytoma (MPC) cell line 9/3L, a cell line that
199 ied, including patients with newly diagnosed pheochromocytoma (n = 29), patients with previously surg
200 ), patients with previously surgically cured pheochromocytoma (n = 31), healthy control subjects (n =
203 88% for the detection of paragangliomas and pheochromocytomas on a patient basis (positive and negat
204 tic angioma, one patient had an extraadrenal pheochromocytoma, one patient had an abscess in the ilio
205 radic VHL-related tumor types, as </= 10% of pheochromocytoma or early-onset renal cell carcinoma and
206 ith a prior history of primary or metastatic pheochromocytoma or paraganglioma and 69 with suspected
207 ytoma or paraganglioma and 69 with suspected pheochromocytoma or paraganglioma based on symptoms of c
212 omide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.
213 udinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence o
215 gliomas (HNP) are very often associated with pheochromocytoma-paraganglioma syndromes, which are caus
217 eir relatives to clinically characterize the pheochromocytoma/paraganglioma diseases associated with
218 The majority of patients with metastatic pheochromocytoma/paraganglioma who presented with a prim
219 nd that patients who present with metastatic pheochromocytoma/paraganglioma with primary tumor develo
220 g a predisposition for renal cell carcinoma, pheochromocytoma/paraganglioma, cerebral hemangioblastom
221 cular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortica
222 n proven to be a highly sensitive method for pheochromocytomas/paragangliomas (PHEOs/PGLs) associated
224 plex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE P
226 HL, suggesting that both genes contribute to pheochromocytoma pathogenesis in a subset of tumors.
227 l fibronectin matrix assembly contributes to pheochromocytoma pathogenesis in the setting of VHL dise
230 ry for patients with biochemical evidence of pheochromocytoma, patients with tumors greater than 6 cm
231 ctate, Hoechst 33342, and FITC dyes upon the pheochromocytoma PC-12 cells and RAW 264.7 macrophages.
232 Evans rats, and cultured differentiated rat pheochromocytoma PC-12 cells, are analyzed before and af
234 c signaling using clones of undifferentiated pheochromocytoma (PC-12) cells that stably overexpress t
237 egated and fibrillar Abeta, and protects rat pheochromocytoma PC12 cells from Abeta toxicity, without
244 al as positive or negative regulators in rat pheochromocytoma (PC12) and fibroblast (normal rat kidne
248 ined their level and mode of toxicity on rat pheochromocytoma (PC12) cells in both differentiated and
249 inst cytochrome c-induced apoptosis in naive pheochromocytoma (PC12) cells, but were remarkably effec
250 olanzapine also provided neuroprotection to pheochromocytoma (PC12) cells, SH-SY5Y neuroblastoma cel
263 py-free interval in patients with metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs).
267 tification of unique molecular signatures in pheochromocytomas (PHEOs) and paragangliomas (PGLs).
268 enesis of the most aggressive and metastatic pheochromocytomas (PHEOs) and paragangliomas (PGLs).
269 ereas specific point mutations predispose to pheochromocytoma, polycythemia, or combinations of heman
270 ested most prominently in the development of pheochromocytoma, prompting an analysis of genes and loc
271 iated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, a
272 roendocrine cell line PC12, derived from rat pheochromocytoma, provides an example of how one canonic
273 with neuroblastoma and 5 with paraganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of (18)
277 tudy characterizing the cardiac phenotype in pheochromocytoma showed that cardiac involvement was fre
278 OH) within both sporadic and MEN2-associated pheochromocytomas, suggesting that they may contribute t
279 ne MAX mutations in patients with hereditary pheochromocytoma supports the predominant role of MAX as
283 vine adrenomedullary chromaffin cells, human pheochromocytoma tissue, PC12 pheochromocytoma cells, an
284 cularly those with the carcinoid syndrome or pheochromocytoma, to undergo surgery safely, with minima
285 lar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were
286 the largest series of patients with familial pheochromocytoma undergoing adrenalectomy during the lap
287 rized the cardiac phenotype in patients with pheochromocytoma using cardiac magnetic resonance (CMR).
290 A or (18)F-FDG PET/CT for known or suspected pheochromocytoma were reviewed retrospectively to determ
292 anced CT can safely be used in patients with pheochromocytoma who are not receiving alpha- or beta-bl
294 m-based array identified a total of 18 of 62 pheochromocytomas with LOH within the chromosome 2 regio
296 shared activation of the hypoxic response in pheochromocytomas with mutations in VHL and SDH genes an
297 diagnosis, treatment, and pathophysiology of pheochromocytoma, with the objective of developing new g
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。